Advances towards the discovery of GPR55 ligands

Current Medicinal Chemistry

Volumn 23, Issue 20, 2016, Pages 2087-2100

  Morales, Paula ^a   Jagerovic, Nadine ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Agonist; Antagonist; Cannabinoid; Endocannabinoid; GPCR; GPR55; Structure

Indexed keywords

AMINOALKYLINDOLE; ARYLPYRAZOLE; CANNABINOID; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR ANTAGONIST; COUMARIN DERIVATIVE; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MAGNOLOL; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; GPR55 PROTEIN, HUMAN; LIGAND; PIPERAZINE DERIVATIVE; PROTEIN BINDING; PYRAZOLE DERIVATIVE;

ARTICLE; BONE; DIABETES MELLITUS; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PHYSIOLOGY; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM;

CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; DRUG DISCOVERY; ENDOCANNABINOIDS; HUMANS; LIGANDS; PIPERAZINES; PROTEIN BINDING; PYRAZOLES; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84983672105     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160504104133     Document Type: Article

References (88)

1. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N-O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152(7), 1092-1101. [http://dx.doi.org/10.1038/sj.bjp.0707460] [PMID: 17876302].
2. Johns, D.G.; Behm, D.J.; Walker, D.J.; Ao, Z.; Shapland, E.M.; Daniels, D.A.; Riddick, M.; Dowell, S.; Staton, P.C.; Green, P.; Shabon, U.; Bao, W.; Aiyar, N.; Yue, T-L.; Brown, A.J.; Morrison, A.D.; Douglas, S.A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol., 2007, 152(5), 825-831. [http://dx.doi.org/10.1038/sj.bjp.0707419] [PMID: 17704827].
3. Sawzdargo, M.; Nguyen, T.; Lee, D.K.; Lynch, K.R.; Cheng, R.; Heng, H.H.Q.; George, S.R.; O'Dowd, B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol. Brain Res., 1999, 64(2), 193-198. [http://dx.doi.org/10.1016/S0169-328X(98)00277-0] [PMID: 9931487].
4. Drmota, P.; Greasley, P.; Groblewski, T. Screening assays for cannabinoid-ligand-type modulators. Astra Zeneca, Patent WO2004074844, 2004.
5. Wise, A.; Brown, A.J. Identification of modulators of GPR55 activity. GlaxoSmithKline Patent WO200186305, 2001.
6. Ross, R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci., 2009, 30(3), 156-163. [http://dx.doi.org/10.1016/j.tips.2008.12.004] [PMID: 19233486].
7. GPR18, GPR55 and GPR119: GPR55. IUPHAR/BPS Guide to Pharmacology. http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=109, Accessed on Aug 17, 2015.
8. Pertwee, R.G.; Howlett, A.C.; Abood, M.E.; Alexander, S.P.; Di Marzo, V.; Elphick, M.R.; Greasley, P.J.; Hansen, H.S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R.A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol. Rev., 2010, 62(4), 588-631. [http://dx.doi.org/10.1124/pr.110.003004] [PMID: 21079038].
9. Shore, D.M.; Reggio, P.H. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front. Pharmacol., 2015, 6, 69. [http://dx.doi.org/10.3389/fphar.2015.00069] [PMID: 25926795].
10. Elbegdorj, O.; Westkaemper, R.B.; Zhang, Y. A homology modeling study toward the understanding of threedimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55. J. Mol. Graph. Model., 2013, 39, 50-60. [http://dx.doi.org/10.1016/j.jmgm.2012.10.005] [PMID: 23220281].
11. Kotsikorou, E.; Madrigal, K.E.; Hurst, D.P.; Sharir, H.; Lynch, D.L.; Heynen-Genel, S.; Milan, L.B.; Chung, T.D.Y.; Seltzman, H.H.; Bai, Y.; Caron, M.G.; Barak, L.; Abood, M.E.; Reggio, P.H. Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry, 2011, 50(25), 5633-5647. [http://dx.doi.org/10.1021/bi200010k] [PMID: 21534610].
12. Sharir, H.; Abood, M.E. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther., 2010, 126(3), 301-313. [http://dx.doi.org/10.1016/j.pharmthera.2010.02.004] [PMID: 20298715].
13. Kotsikorou, E.; Sharir, H.; Shore, D.M.; Hurst, D.P.; Lynch, D.L.; Madrigal, K.E.; Heynen-Genel, S.; Milan, L.B.; Chung, T.D.Y.; Seltzman, H.H.; Bai, Y.; Caron, M.G.; Barak, L.S.; Croatt, M.P.; Abood, M.E.; Reggio, P.H. Identification of the GPR55 antagonist binding site using a novel set of highpotency GPR55 selective ligands. Biochemistry, 2013, 52(52), 9456-9469. [http://dx.doi.org/10.1021/bi4008885] [PMID: 24274581].
14. Gasperi, V.; Dainese, E.; Oddi, S.; Sabatucci, A.; Maccarrone, M. GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors. Curr. Med. Chem., 2013, 20(1), 64-78. [http://dx.doi.org/10.2174/0929867311302010008] [PMID: 23151004].
15. Moriconi, A.; Cerbara, I.; Maccarrone, M.; Topai, A. GPR55: Current knowledge and future perspectives of a purported "Type-3" cannabinoid receptor. Curr. Med. Chem., 2010, 17(14), 1411-1429. [http://dx.doi.org/10.2174/092986710790980069] [PMID: 20166924].
16. Nevalainen, T.; Irving, A.J. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr. Top. Med. Chem., 2010, 10(8), 799-813. [http://dx.doi.org/10.2174/156802610791164229] [PMID: 20370712].
17. Childers, S.R.; Deadwyler, S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol., 1996, 52(6), 819-827. [http://dx.doi.org/10.1016/0006-2952(96)00419-4] [PMID: 8781498].
18. Bonhaus, D.W.; Chang, L.K.; Kwan, J.; Martin, G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: Evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther., 1998, 287(3), 884-888. [PMID: 9864268].
19. 2+signaling and NFAT activation. FASEB J., 2009, 23(1), 183-193. [http://dx.doi.org/10.1096/fj.08-108670] [PMID: 18757503].
20. 2+signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci., 2008, 121(Pt 10), 1704-1717. [http://dx.doi.org/10.1242/jcs.020958] [PMID: 18445684].
21. Lauckner, J.E.; Jensen, J.B.; Chen, H-Y.; Lu, H-C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA, 2008, 105(7), 2699-2704. [http://dx.doi.org/10.1073/pnas.0711278105] [PMID: 18263732].
22. Henstridge, C.M.; Balenga, N.A.; Schroder, R.; Kargl, J.K.; Platzer, W.; Martini, L.; Arthur, S.; Penman, J.; Whistler, J.L.; Kostenis, E.; Waldhoer, M.; Irving, A.J. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br. J. Pharmacol., 2010, 160(3), 604-614. [http://dx.doi.org/10.1111/j.1476-5381.2009.00625.x] [PMID: 20136841].
23. Rempel, V.; Volz, N.; Glaser, F.; Nieger, M.; Brase, S.; Muller, C.E. Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J. Med. Chem., 2013, 56(11), 4798-4810. [http://dx.doi.org/10.1021/jm4005175] [PMID: 23679955].
24. Funke, M.; Thimm, D.; Schiedel, A.C.; Muller, C.E. 8- Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35. J. Med. Chem., 2013, 56(12), 5182-5197. [http://dx.doi.org/10.1021/jm400587g] [PMID: 23713606].
25. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362(4), 928-934. [http://dx.doi.org/10.1016/j.bbrc.2007.08.078] [PMID: 17765871].
26. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: A possible natural ligand for GPR55. J. Biochem., 2009, 145(1), 13-20. [http://dx.doi.org/10.1093/jb/mvn136] [PMID: 18845565].
27. Henstridge, C.M. Off-target cannabinoid effects mediated by GPR55. Pharmacology, 2012, 89(3-4), 179-187. [http://dx.doi.org/10.1159/000336872] [PMID: 22433274].
28. Park, P.S.H. Ensemble of G protein-coupled receptor active states. Curr. Med. Chem., 2012, 19(8), 1146-1154. [http://dx.doi.org/10.2174/092986712799320619] [PMID: 22300048].
29. Audet, M.; Bouvier, M. Restructuring G-protein- coupled receptor activation. Cell, 2012, 151(1), 14-23. [http://dx.doi.org/10.1016/j.cell.2012.09.003] [PMID: 23021212].
30. Moreno, E.; Andradas, C.; Medrano, M.; Caffarel, M.M.; Perez-Gomez, E.; Blasco-Benito, S.; Gomez-Canas, M.; Pazos, M.R.; Irving, A.J.; Lluis, C.; Canela, E.I.; Fernandez- Ruiz, J.; Guzman, M.; McCormick, P.J.; Sanchez, C. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J. Biol. Chem., 2014, 289(32), 21960-21972. [http://dx.doi.org/10.1074/jbc.M114.561761] [PMID: 24942731].
31. Balenga, N.A.; Martinez-Pinilla, E.; Kargl, J.; Schroder, R.; Peinhaupt, M.; Platzer, W.; Balint, Z.; Zamarbide, M.; Dopeso-Reyes, I.G.; Ricobaraza, A.; Perez-Ortiz, J.M.; Kostenis, E.; Waldhoer, M.; Heinemann, A.; Franco, R. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. Br. J. Pharmacol., 2014, 171(23), 5387-5406. [http://dx.doi.org/10.1111/bph.12850] [PMID: 25048571].
32. Anavi-Goffer, S.; Baillie, G.; Irving, A.J.; Gertsch, J.; Greig, I.R.; Pertwee, R.G.; Ross, R.A. Modulation of L-α- lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem., 2012, 287(1), 91-104. [http://dx.doi.org/10.1074/jbc.M111.296020] [PMID: 22027819].
33. Kenakin, T.P. Cellular assays as portals to seventransmembrane receptor-based drug discovery. Nat. Rev. Drug Discov., 2009, 8(8), 617-626. [http://dx.doi.org/10.1038/nrd2838] [PMID: 19609267].
34. Venkatakrishnan, A.J.; Deupi, X.; Lebon, G.; Tate, C.G.; Schertler, G.F.; Babu, M.M. Molecular signatures of Gprotein- coupled receptors. Nature, 2013, 494(7436), 185-194. [http://dx.doi.org/10.1038/nature11896] [PMID: 23407534].
35. Morales, P.; Whyte, L.S.; Chicharro, R.; Gomez-Canas, M.; Pazos, M.R.; Goya, P.; Irving, A.J.; Fernandez-Ruiz, J.; Ross, R.A.; Jagerovic, N. Identification of novel receptor GPR35, GPR55 modulators using cell-impedance-based label free technology. J. Med. Chem., 2016, 59(5), 1840-1853. [http://dx.doi.org/10.1021/acs.jmedchem.5b01331] [PMID: 26789378].
36. Henstridge, C.M.; Balenga, N.A.B.; Kargl, J.; Andradas, C.; Brown, A.J.; Irving, A.; Sanchez, C.; Waldhoer, M. Minireview: Recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol. Endocrinol., 2011, 25(11), 1835-1848. [http://dx.doi.org/10.1210/me.2011-1197] [PMID: 21964594].
37. Balenga, N.A.B.; Henstridge, C.M.; Kargl, J.; Waldhoer, M. Pharmacology of G Protein Coupled Receptors. In: Pharmacology, Signaling and Physiological Relevance of the G Protein-Coupled Receptor 55, 1st ed.; Elsevier Inc.: UK, 2011, Vol. 62, pp. 251-279. [http://dx.doi.org/10.1016/B978-0-12-385952-5.00004-X].
38. Sylantyev, S.; Jensen, T.P.; Ross, R.A.; Rusakov, D.A. Cannabinoid- And lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc. Natl. Acad. Sci. USA, 2013, 110(13), 5193-5198. [http://dx.doi.org/10.1073/pnas.1211204110] [PMID: 23472002].
39. Staton, P.C.; Hatcher, J.P.; Walker, D.J.; Morrison, A.D.; Shapland, E.M.; Hughes, J.P.; Chong, E.; Mander, P.K.; Green, P.J.; Billinton, A.; Fulleylove, M.; Lancaster, H.C.; Smith, J.C.; Bailey, L.T.; Wise, A.; Brown, A.J.; Richardson, J.C.; Chessell, I.P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain, 2008, 139(1), 225-236. [http://dx.doi.org/10.1016/j.pain.2008.04.006] [PMID: 18502582].
40. Deliu, E.; Sperow, M.; Console-Bram, L.; Carter, R.L.; Tilley, D.G.; Kalamarides, D.J.; Kirby, L.G.; Brailoiu, G.C.; Brailoiu, E.; Benamar, K.; Abood, M.E. The lysophosphatidylinositol receptor GPR55 modulates pain perception in the periaqueductal gray. Mol. Pharmacol., 2015, 88(2), 265-272. [http://dx.doi.org/10.1124/mol.115.099333] [PMID: 25972448].
41. Gangadharan, V.; Selvaraj, D.; Kurejova, M.; Njoo, C.; Gritsch, S.; Škoricova, D.; Horstmann, H.; Offermanns, S.; Brown, A.J.; Kuner, T.; Tappe-Theodor, A.; Kuner, R. A novel biological role for the phospholipid lysophosphatidylinositol in nociceptive sensitization via activation of diverse G-protein signalling pathways in sensory nerves in vivo. Pain, 2013, 154(12), 2801-2812. [http://dx.doi.org/10.1016/j.pain.2013.08.019] [PMID: 23973358].
42. Pietr, M.; Kozela, E.; Levy, R.; Rimmerman, N.; Lin, Y.H.; Stella, N.; Vogel, Z.; Juknat, A. Differential changes in GPR55 during microglial cell activation. FEBS Lett., 2009, 583(12), 2071-2076. [http://dx.doi.org/10.1016/j.febslet.2009.05.028] [PMID: 19464294].
43. Balenga, N.A.B.; Aflaki, E.; Kargl, J.; Platzer, W.; Schroder, R.; Blattermann, S.; Kostenis, E.; Brown, A.J.; Heinemann, A.; Waldhoer, M. GPR55 regulates cannabinoid 2 receptormediated responses in human neutrophils. Cell Res., 2011, 21(10), 1452-1469. [http://dx.doi.org/10.1038/cr.2011.60] [PMID: 21467997].
44. Romero-Zerbo, S.Y.; Rafacho, A.; Diaz-Arteaga, A.; Suarez, J.; Quesada, I.; Imbernon, M.; Ross, R.A.; Dieguez, C.; Rodriguez de Fonseca, F.; Nogueiras, R.; Nadal, A.; Bermudez-Silva, F.J. A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J. Endocrinol., 2011, 211(2), 177-185. [http://dx.doi.org/10.1530/JOE-11-0166] [PMID: 21885477].
45. Diaz-Arteaga, A.; Vazquez, M.J.; Vazquez-Martinez, R.; Pulido, M.R.; Suarez, J.; Velasquez, D.A.; Lopez, M.; Ross, R.A.; de Fonseca, F.R.; Bermudez-Silva, F.J.; Malagon, M.M.; Dieguez, C.; Nogueiras, R. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes. Metab., 2012, 14(3), 234-243. [http://dx.doi.org/10.1111/j.1463-1326.2011.01515.x] [PMID: 21981246].
46. Liu, B.; Song, S.; Jones, P.M.; Persaud, S.J. GPR55: from orphan to metabolic regulator? Pharmacol. Ther., 2015, 145, 35-42. [http://dx.doi.org/10.1016/j.pharmthera.2014.06.007] [PMID: 24972076].
47. Jenkin, K.A.; McAinch, A.J.; Zhang, Y.; Kelly, D.J.; Hryciw, D.H. Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions. Clin. Exp. Pharmacol. Physiol., 2015, 42(3), 256-262. [http://dx.doi.org/10.1111/1440-1681.12355] [PMID: 25545857].
48. Lanuti, M.; Talamonti, E.; Maccarrone, M.; Chiurchiu, V. Activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human macrophages. PLoS One, 2015, 10(5), e0126839. [http://dx.doi.org/10.1371/journal.pone.0126839] [PMID: 25970609].
49. Meadows, A.; Lee, J.H.; Wu, C-S.; Wei, Q.; Pradhan, G.; Yafi, M.; Lu, H-C.; Sun, Y. Deletion of G-protein coupled receptor 55 promotes obesity by reducing physical activity. Int. J. Obes., 2016, 40(3), 417-424. [PMID: 26447738].
50. Bondarenko, A.; Waldeck-Weiermair, M.; Naghdi, S.; Poteser, M.; Malli, R.; Graier, W.F. GPR55-dependent and - independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br. J. Pharmacol., 2010, 161(2), 308-320. [http://dx.doi.org/10.1111/j.1476-5381.2010.00744.x] [PMID: 20735417].
51. Daly, C.J.; Ross, R.A.; Whyte, J.; Henstridge, C.M.; Irving, A.J.; McGrath, J.C. Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid- like' receptors in small arteries. Br. J. Pharmacol., 2010, 159(4), 787-796. [http://dx.doi.org/10.1111/j.1476-5381.2009.00608.x] [PMID: 20136833].
52. 2+release in rat mesenteric artery endothelial cells. Br. J. Pharmacol., 2015, 172(12), 3043-3057. [http://dx.doi.org/10.1111/bph.13107] [PMID: 25652040].
53. Falasca, M.; Ferro, R. Role of the lysophosphatidylinositol/GPR55 axis in cancer. Adv. Biol. Regul., 2016, 60, 88-93. [http://dx.doi.org/10.1016/j.jbior.2015.10.003] [PMID: 26588872].
54. Xiao, Y.J.; Schwartz, B.; Washington, M.; Kennedy, A.; Webster, K.; Belinson, J.; Xu, Y. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal. Biochem., 2001, 290(2), 302-313. [http://dx.doi.org/10.1006/abio.2001.5000] [PMID: 11237333].
55. Sutphen, R.; Xu, Y.; Wilbanks, G.D.; Fiorica, J.; Grendys, E.C. Jr.; LaPolla, J.P.; Arango, H.; Hoffman, M.S.; Martino, M.; Wakeley, K.; Griffin, D.; Blanco, R.W.; Cantor, A.B.; Xiao, Y.J.; Krischer, J.P. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2004, 13(7), 1185-1191. [PMID: 15247129].
56. Andradas, C.; Caffarel, M.M.; Perez-Gomez, E.; Salazar, M.; Lorente, M.; Velasco, G.; Guzman, M.; Sanchez, C. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene, 2011, 30(2), 245-252. [http://dx.doi.org/10.1038/onc.2010.402] [PMID: 20818416].
57. Perez-Gomez, E.; Andradas, C.; Flores, J.M.; Quintanilla, M.; Paramio, J.M.; Guzman, M.; Sanchez, C. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene, 2013, 32(20), 2534-2542. [http://dx.doi.org/10.1038/onc.2012.278] [PMID: 22751111].
58. Karlsson, R.; Pedersen, E.D.; Wang, Z.; Brakebusch, C. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta, 2009, 1796, 91-98. [http://dx.doi.org/10.1016/j.bbcan.2009.03.003].
59. He, D.; Wang, J.; Zhang, C.; Shan, B.; Deng, X.; Li, B.; Zhou, Y.; Chen, W.; Hong, J.; Gao, Y.; Chen, Z.; Duan, C. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol. Cancer, 2015, 14, 73. [http://dx.doi.org/10.1186/s12943-015-0342-0] [PMID: 25889562].
60. Hofmann, N.A.; Yang, J.; Trauger, S.A.; Nakayama, H.; Huang, L.; Strunk, D.; Moses, M.A.; Klagsbrun, M.; Bischoff, J.; Graier, W.F. The GPR 55 agonist, L-α- lysophosphatidylinositol, mediates ovarian carcinoma cellinduced angiogenesis. Br. J. Pharmacol., 2015, 172(16), 4107-4118. [http://dx.doi.org/10.1111/bph.13196] [PMID: 25989290].
61. Kargl, J.; Andersen, L.; Hasenohrl, C.; Feuersinger, D.; Stančić, A.; Fauland, A.; Magnes, C.; El-Heliebi, A.; Lax, S.; Uranitsch, S.; Haybaeck, J.; Heinemann, A.; Schicho, R. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br. J. Pharmacol., 2016, 173(1), 142-154. [http://dx.doi.org/10.1111/bph.13345] [PMID: 26436760].
62. Whyte, L.S.; Ryberg, E.; Sims, N.A.; Ridge, S.A.; Mackie, K.; Greasley, P.J.; Ross, R.A.; Rogers, M.J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. USA, 2009, 106(38), 16511-16516. [http://dx.doi.org/10.1073/pnas.0902743106] [PMID: 19805329].
63. Wu, C-S.; Chen, H.; Sun, H.; Zhu, J.; Jew, C.P.; Wager- Miller, J.; Straiker, A.; Spencer, C.; Bradshaw, H.; Mackie, K.; Lu, H-C. GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination. PLoS One, 2013, 8(4), e60314. [http://dx.doi.org/10.1371/journal.pone.0060314] [PMID: 23565223].
64. Okuno, T.; Yokomizo, T. What is the natural ligand of GPR55? J. Biochem., 2011, 149(5), 495-497. [http://dx.doi.org/10.1093/jb/mvr022] [PMID: 21324983].
65. Dorsam, R.T.; Gutkind, J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer, 2007, 7(2), 79-94. [http://dx.doi.org/10.1038/nrc2069] [PMID: 17251915].
66. Lin, M-E.; Herr, D.R.; Chun, J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat., 2010, 91(3-4), 130-138. [http://dx.doi.org/10.1016/j.prostaglandins.2009.02.002] [PMID: 20331961].
67. Pyne, N.J.; Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 2010, 10(7), 489-503. [http://dx.doi.org/10.1038/nrc2875] [PMID: 20555359].
68. Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D.G.; Caldwell, J.S.; Chen, Y.A.; Lipid, G. Lipid G protein-coupled receptor ligand identification using betaarrestin PathHunter assay. J. Biol. Chem., 2009, 284(18), 12328-12338. [http://dx.doi.org/10.1074/jbc.M806516200] [PMID: 19286662].
69. Guy, A.T.; Nagatsuka, Y.; Ooashi, N.; Inoue, M.; Nakata, A.; Greimel, P.; Inoue, A.; Nabetani, T.; Murayama, A.; Ohta, K.; Ito, Y.; Aoki, J.; Hirabayashi, Y.; Kamiguchi, H. Glycerophospholipid regulation of modality-specific sensory axon guidance in the spinal cord. Science, 2015, 349(6251), 974-977. [http://dx.doi.org/10.1126/science.aab3516] [PMID: 26315437].
70. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M.G.; Barak, L.S.; Abood, M.E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem., 2009, 284(43), 29817-29827. [http://dx.doi.org/10.1074/jbc.M109.050187] [PMID: 19723626].
71. Kotsikorou, E.; Lynch, D.L.; Abood, M.E.; Reggio, P.H. Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Chem. Phys. Lipids, 2011, 164(2), 131-143. [http://dx.doi.org/10.1016/j.chemphyslip.2010.12.003] [PMID: 21185816].
72. Ford, L.A.; Roelofs, A.J.; Anavi-Goffer, S.; Mowat, L.; Simpson, D.G.; Irving, A.J.; Rogers, M.J.; Rajnicek, A.M.; Ross, R.A. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br. J. Pharmacol., 2010, 160(3), 762-771. [http://dx.doi.org/10.1111/j.1476-5381.2010.00743.x] [PMID: 20590578].
73. Offertaler, L.; Mo, F-M.; Batkai, S.; Liu, J.; Begg, M.; Razdan, R.K.; Martin, B.R.; Bukoski, R.D.; Kunos, G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol., 2003, 63(3), 699-705. [http://dx.doi.org/10.1124/mol.63.3.699] [PMID: 12606780].
74. Brown, A.J.; Daniels, D.A.; Kassim, M.; Brown, S.; Haslam, C.P.; Terrell, V.R.; Brown, J.; Nichols, P.L.; Staton, P.C.; Wise, A.; Dowell, S.J. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J. Pharmacol. Exp. Ther., 2011, 337(1), 236-246. [http://dx.doi.org/10.1124/jpet.110.172650] [PMID: 21233197].
75. Pineiro, R.; Maffucci, T.; Falasca, M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene, 2011, 30(2), 142-152.[http://dx.doi.org/10.1038/onc.2010.417] [PMID: 20838378].
76. Valant, C.; Sexton, P.M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Interv., 2009, 9(3), 125-135. [http://dx.doi.org/10.1124/mi.9.3.6] [PMID: 19592673].
77. Rempel, V.; Volz, N.; Hinz, S.; Karcz, T.; Meliciani, I.; Nieger, M.; Wenzel, W.; Brase, S.; Muller, C.E. 7-Alkyl-3- benzylcoumarins: A versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. J. Med. Chem., 2012, 55(18), 7967-7977. [http://dx.doi.org/10.1021/jm3008213] [PMID: 22916707].
78. Deng, F-F.; Xie, M-H.; Li, P-Z.; Tian, Y-L.; Zhang, X-Y.; Zhai, H-L. Study on the antagonists for the orphan G proteincoupled receptor GPR55 by quantitative structure-activity relationship. Chemom. Intell. Lab. Syst., 2014, 131, 51-60. [http://dx.doi.org/10.1016/j.chemolab.2013.12.006].
79. Lee, Y-J.; Lee, Y.M.; Lee, C-K.; Jung, J.K.; Han, S.B.; Hong, J.T. Therapeutic applications of compounds in the Magnolia family. Pharmacol. Ther., 2011, 130(2), 157-176. [http://dx.doi.org/10.1016/j.pharmthera.2011.01.010] [PMID: 21277893].
80. Schuehly, W.; Paredes, J.M.; Kleyer, J.; Huefner, A.; Anavi- Goffer, S.; Raduner, S.; Altmann, K-H.; Gertsch, J. Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem. Biol., 2011, 18(8), 1053-1064. [http://dx.doi.org/10.1016/j.chembiol.2011.05.012] [PMID: 21867920].
81. Rempel, V.; Fuchs, A.; Hinz, S.; Karcz, T.; Lehr, M.; Koetter, U.; Muller, C.E. Magnolia extract, magnolol, and metabolites: Activation of cannabinoid CB2 receptors and blockade of the related GPR55. ACS Med. Chem. Lett., 2013, 4(1), 41-45. [http://dx.doi.org/10.1021/ml300235q] [PMID: 24900561].
82. Fuchs, A.; Rempel, V.; Muller, C.E. The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS One, 2013, 8(10), e77739. [http://dx.doi.org/10.1371/journal.pone.0077739] [PMID: 24204944].
83. Heynen-Genel, S.; Dahl, R.; Shi, S.; Milan, L.; Sergienko, E.; Hedrick, M.; Dad, S.; Stonich, D.; Su, Y.; Chung, T.D.; Sharir, H.; Caron, M.G.; Barak, L.S.; Abood, M.E. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program; National Center for Biotechnology Information: Bethesda, MD, 2010. [U.S.].
84. Heynen-Genel, S.; Dahl, R.; Shi, S.; Milan, L.; Bravo, Y.; Sergienko, E.; Hedrick, M.; Dad, S.; Stonich, D.; Su, Y.; Chung, T.D.; Sharir, H.; Barak, L.S.; Abood, M.E. Screening for Selective Ligands for GPR55-Agonists. Probe Reports from the NIH Molecular Libraries Program; National Center for Biotechnology Information: Bethesda, MD, 2010. [U.S.].
85. Kargl, J.; Brown, A.J.; Andersen, L.; Dorn, G.; Schicho, R.; Waldhoer, M.; Heinemann, A. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J. Pharmacol. Exp. Ther., 2013, 346(1), 54-66. [http://dx.doi.org/10.1124/jpet.113.204180] [PMID: 23639801].
86. Meza-Avina, M.E.; Lingerfelt, M.A.; Console-Bram, L.M.; Gamage, T.F.; Sharir, H.; Gettys, K.E.; Hurst, D.P.; Kotsikorou, E.; Shore, D.M.; Caron, M.G.; Rao, N.; Barak, L.S.; Abood, M.E.; Reggio, P.H.; Croatt, M.P. Design, synthesis, and analysis of antagonists of GPR55: Piperidinesubstituted 1, 3, 4-oxadiazol-2-ones. Bioorg. Med. Chem. Lett., 2016, 26(7), 1827-1830. [http://dx.doi.org/10.1016/j.bmcl.2016.02.030] [PMID: 26916440].
87. Yrjola, S.; Parkkari, T.; Navia-Paldanius, D.; Laitinen, T.; Kaczor, A.A.; Kokkola, T.; Adusei-Mensah, F.; Savinainen, J.R.; Laitinen, J.T.; Poso, A.; Alexander, A.; Penman, J.; Stott, L.; Anskat, M.; Irving, A.J.; Nevalainen, T.J. Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists. Eur. J. Med. Chem., 2016, 107, 119-132. [http://dx.doi.org/10.1016/j.ejmech.2015.10.050] [PMID: 26575458].
88. Paul, R.K.; Wnorowski, A.; Gonzalez-Mariscal, I.; Nayak, S.K.; Pajak, K.; Moaddel, R.; Indig, F.E.; Bernier, M.; Wainer, I.W. (R, R')-4′-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility. Biochem. Pharmacol., 2014, 87(4), 547-561. [http://dx.doi.org/10.1016/j.bcp.2013.11.020] [PMID: 24355564].